Press release, Helsinki, 1 August 2025 at 9 AM (EEST) 

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 5+ System from an existing customer in the US.

The customer has been a long-time user of nTMS and was now able to upgrade their existing system to unlock additional research capabilities.

In addition to the clinical use of motor and language mapping as well as rTMS therapy, the customer will have access to various research features. They will be able to use a biphasic paired pulse module, as well as TMS-EEG functionalities.

The biphasic paired-pulse functionality for pre-procedural motor mapping is an alternative to single-pulse mapping, enabling lower stimulation intensities and extending the use of nTMS to patients with lower corticospinal excitability.

The TMS-EEG functionality enables researchers to measure TMS-evoked cortical reactivity and connectivity by doing TMS stimulation concurrently with EEG measurement.

Mikko Karvinen, CEO of Nexstim, comments: “We are excited to support this innovative customer with new clinical and research features, and are looking forward to their research projects, advancing the field of nTMS!”

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com